Matches in SemOpenAlex for { <https://semopenalex.org/work/W144765624> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W144765624 endingPage "631" @default.
- W144765624 startingPage "628" @default.
- W144765624 abstract "Objective To compare the efficacy and safety of fondaparinux with that of low molecular weight heparin (LMWH) in the treatment of acute coronary syndrome (ACS). Methods One hundred and five patients with ACS admitted from November 2009 to August 2010 were randomly divided into two groups. They were all treated with nitrates, β-blockers, angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), statins, clopidogrel, enteric-coated aspirin and other basic drugs. On the basis of the above treatment, the fondaparinux group patients (n=50) received hypodermic injection of fondaparinux 2.5 mg, once a day, and the LMWH group patients (n=55) received hypodermic injection of LMWH 0.4 ml, twice a day, the therapeutic course being 3- 8 days of both groups. The therapeutic efficacy, the cardiovascular event and bleeding incidences during 7 days and 30 days of the treatment were observed. Results There was no significant difference between the fondaparinux group and LMWH group in the total effective rate (96.0% vs. 92.7%, P＞0.05), also no significant differences were found between the two groups in cardiovascular events (death, acute myocardial infarction and recurrence of myocardial infarction) during 7 days and 30 days (7 days: 4.0% vs. 7.3%, 30 days: 8.0% vs. 10.9%, both P＞0.05). There was no major bleeding incident, and the incidence of minor bleeding in fondaparinux group was obviously lower than that in LMWH group (2.0% vs. 32.7%, P＜0.01). Conclusion The efficacy of fondaparinux in the treatment of ACS is not inferior to that of LMWH, and adverse events during and after its administration were significantly lower than those in LMWH group, so that fondaparinux treatment for ACS is safe and can be highly recommended.Key words: Acute coronary syndromes; Fondaparinux; Low molecular weight heparin; Anticoagulation" @default.
- W144765624 created "2016-06-24" @default.
- W144765624 creator A5028580733 @default.
- W144765624 creator A5039219377 @default.
- W144765624 creator A5040190424 @default.
- W144765624 creator A5070509723 @default.
- W144765624 date "2010-01-30" @default.
- W144765624 modified "2023-09-27" @default.
- W144765624 title "Comparison of therapeutic efficacy between fondaparinux and low molecular weight heparin for patients with acute coronary syndrome" @default.
- W144765624 doi "https://doi.org/10.3760/cma.j.issn.1003-0603.2010.10.018" @default.
- W144765624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20977850" @default.
- W144765624 hasPublicationYear "2010" @default.
- W144765624 type Work @default.
- W144765624 sameAs 144765624 @default.
- W144765624 citedByCount "0" @default.
- W144765624 crossrefType "journal-article" @default.
- W144765624 hasAuthorship W144765624A5028580733 @default.
- W144765624 hasAuthorship W144765624A5039219377 @default.
- W144765624 hasAuthorship W144765624A5040190424 @default.
- W144765624 hasAuthorship W144765624A5070509723 @default.
- W144765624 hasConcept C126322002 @default.
- W144765624 hasConcept C164705383 @default.
- W144765624 hasConcept C2776877702 @default.
- W144765624 hasConcept C2776884760 @default.
- W144765624 hasConcept C2777557582 @default.
- W144765624 hasConcept C2777628954 @default.
- W144765624 hasConcept C2777698277 @default.
- W144765624 hasConcept C2777849778 @default.
- W144765624 hasConcept C2780868729 @default.
- W144765624 hasConcept C2991741193 @default.
- W144765624 hasConcept C42219234 @default.
- W144765624 hasConcept C500558357 @default.
- W144765624 hasConcept C71924100 @default.
- W144765624 hasConcept C90924648 @default.
- W144765624 hasConceptScore W144765624C126322002 @default.
- W144765624 hasConceptScore W144765624C164705383 @default.
- W144765624 hasConceptScore W144765624C2776877702 @default.
- W144765624 hasConceptScore W144765624C2776884760 @default.
- W144765624 hasConceptScore W144765624C2777557582 @default.
- W144765624 hasConceptScore W144765624C2777628954 @default.
- W144765624 hasConceptScore W144765624C2777698277 @default.
- W144765624 hasConceptScore W144765624C2777849778 @default.
- W144765624 hasConceptScore W144765624C2780868729 @default.
- W144765624 hasConceptScore W144765624C2991741193 @default.
- W144765624 hasConceptScore W144765624C42219234 @default.
- W144765624 hasConceptScore W144765624C500558357 @default.
- W144765624 hasConceptScore W144765624C71924100 @default.
- W144765624 hasConceptScore W144765624C90924648 @default.
- W144765624 hasIssue "10" @default.
- W144765624 hasLocation W1447656241 @default.
- W144765624 hasLocation W1447656242 @default.
- W144765624 hasOpenAccess W144765624 @default.
- W144765624 hasPrimaryLocation W1447656241 @default.
- W144765624 hasRelatedWork W114213478 @default.
- W144765624 hasRelatedWork W2023225394 @default.
- W144765624 hasRelatedWork W2060628396 @default.
- W144765624 hasRelatedWork W2095901832 @default.
- W144765624 hasRelatedWork W2156496314 @default.
- W144765624 hasRelatedWork W2159553511 @default.
- W144765624 hasRelatedWork W2344456832 @default.
- W144765624 hasRelatedWork W2349862991 @default.
- W144765624 hasRelatedWork W2365087043 @default.
- W144765624 hasRelatedWork W2367032942 @default.
- W144765624 hasRelatedWork W2368632853 @default.
- W144765624 hasRelatedWork W2375104915 @default.
- W144765624 hasRelatedWork W2379664367 @default.
- W144765624 hasRelatedWork W2384140924 @default.
- W144765624 hasRelatedWork W2384714961 @default.
- W144765624 hasRelatedWork W2410383093 @default.
- W144765624 hasRelatedWork W2418367129 @default.
- W144765624 hasRelatedWork W2592857880 @default.
- W144765624 hasRelatedWork W3031193283 @default.
- W144765624 hasRelatedWork W67109507 @default.
- W144765624 hasVolume "22" @default.
- W144765624 isParatext "false" @default.
- W144765624 isRetracted "false" @default.
- W144765624 magId "144765624" @default.
- W144765624 workType "article" @default.